Mutational processes shape the landscape of TP53 mutations in human cancer
2018 · Nature Genetics · 566 citations
https://doi.org/10.1038/s41588-018-0204-y
H
Hugh Gannon
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
51
Papers
1.3K
Citations
12
h-index
12
i10-index
Hugh Gannon is an academic researcher from Q Therapeutics (United States). The author has contributed to research in topics: PARP inhibition in cancer therapy & CRISPR and Genetic Engineering & DNA Repair Mechanisms. The author has an h-index of 12, co-authored 44 publications.
ORCID: 0000-0003-0923-7330Papers by this author
worksIdentification of ADAR1 adenosine deaminase dependency in a subset of cancer cells
2018 · Nature Communications · 244 citations
https://doi.org/10.1038/s41467-018-07824-4
Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis
2016 · Cell Reports · 31 citations
https://doi.org/10.1016/j.celrep.2016.08.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat